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DIALYSIS – TRANSPLANTATION
New onset hyperglycemia and diabetes are associated with
increased cardiovascular risk after kidney transplantation
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New onset hyperglycemia and diabetes are associated with
increased cardiovascular risk after kidney transplantation.
Background. Post-transplant diabetes (PTDM) is a common
and serious complication of kidney transplantation. The impli-
cations of developing hyperglycemia of lesser severity are not
well understood.
Methods. In this study we used American Diabetes Asso-
ciation (ADA) criteria to assess the incidence of abnormal
glycemia post-transplant, the variables that relate to this com-
plication, and the relationship between hyperglycemia and car-
diovascular (CV) disease. Included in the study were 490 kidney
recipients, transplanted from 1998 to 2003, without a history of
diabetes, and with a pretransplant fasting glucose <126 mg/dL.
Results. Within one week post-transplant, 45% of recipients
had impaired fasting glycemia (IFG, glucose 100–125 mg/dL),
and 21% PTDM (glucose ≥126). One year post-transplant, 33%
of patients had IFG, and 13% PTDM. Risk factors for hyper-
glycemia at one year included: older recipient, male gender,
higher BMI, higher pretransplant glucose, and higher glucose
one week post-transplant (all P < 0.002 by multivariable anal-
yses). During a follow-up period of 40 ± 14 months, 12% of
recipients had CV events (cardiac, CVA, and/or peripheral).
Increasing fasting glucose levels at one, four, and/or 12 months
post-transplant were significantly related to CV events. Fur-
thermore, these relationships were independent of other CV
risk factors, including: older age, CV events pretransplant, male
gender, dyslipidemia, and transplant year. Fasting glucose lev-
els >100 mg/dL were associated with higher incidence of post-
transplant cardiac (P = 0.001) and peripheral vascular disease
events (P = 0.003).
Conclusion. The incidence of post-transplant hyperglycemia
and its CV impact have been underestimated. Pretransplant
characteristics and, particularly, the glycemia during the first
month post-transplant identified patients at risk of PTDM. In-
creasing glucose levels greater than 100 mg/dL, any time after
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the first month post-transplant, are associated with increasing
CV risk. We postulate that aggressive detection and treatment
of post-transplant hyperglycemia may significantly reduce CV
morbidity and mortality after kidney transplantation.
Post-transplant diabetes (PTDM), also called new on-
set diabetes (NODM), is recognized as a common and se-
vere complication of kidney transplantation (reviewed in
[1–3]). In recent years, there has been a renewed interest
in PTDM because of its increasing incidence, association
with increased morbidity, and negative impact on patient
and graft survival [1, 2, 4–7]. However, studies on PTDM
are limited by the criteria used for the diagnosis of this
disease. For example, the incidence of PTDM has been
estimated based on the use of hypoglycemic agents [5],
or based on clinical diagnosis of diabetes [6]. However,
studies in the general population [8] suggest that these
diagnostic approaches likely underestimate the true inci-
dence of diabetes in the transplant population. In these
studies we sought to determine the incidence of abnormal
glucose metabolism post-transplant utilizing diagnostic
criteria proposed by an American Diabetes Association
(ADA) expert panel on diagnosis and classification of
diabetes [9, 10]. We focused these studies on the abnor-
malities in glycemia that occur during the first year post-
transplant in part because this is the period of highest
risk for developing PTDM [4, 6] and, in part, based on
the postulate that patients who develop PTDM after the
first year likely have hyperglycemia prior to that time.
The ADA diagnostic criteria are principally based on
the relationship between elevated levels of fasting plasma
glucose and diabetic retinopathy [9, 10]. However, hyper-
glycemia also relates to cardiovascular (CV) disease and
mortality [11, 12]. The aims of these studies were to assess
the incidence of hyperglycemia following kidney trans-
plantation, and to determine the risk of CV complications
in these patients. These analyses show that hyperglycemia
was quite common following kidney transplantation.
Furthermore, all levels of fasting hyperglycemia were
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Table 1. Patient characteristics
Variable Values
Number of patients 490
Donor type (deceased/living) 138 (28%)/352 (72%)
Recipient age 49.3 ± 14
Recipient sex (% male) 59%
Recipient race (% Caucasian) 91%
Dialysis pretransplant 57%
Recipient BMIa 27 ± 5 (15–51)
Recipient pretransplant chemistriesb
Glucose 93 ± 11 (52–125)
Glucose >100 mg/dL (IFG) 25%
Cholesterol 192 ± 48 (86–382)
Triglycerides 192 ± 125 (38–1101)
LDL 109 ± 38 (10–240)
HDL 47 ± 16 (16–137)
Uric acid 6.7 ± 2.1 (2.4–15)
Hepatitis C (N,% positive) 6 (1.2%)
Transplant number (% first) 82%
Acute rejection (N,%) 35 (14%)
a Body mass index (BMI) was calculated as weight (kg)/height (m2).
bAll values in mg/dL
associated with increased CV risk. Thus, it is likely that we
have underestimated both the incidence and the conse-
quences of this post-transplant complication in the past.
We postulate that prompt diagnosis and treatment of
post-transplant hyperglycemia may well lead to improved
patient survival after kidney transplantation.
METHODS
Patient population
These analyses were based on a population of 490 adult
kidney transplant recipients who received their allograft
at our institution between January 1998 and May 2003.
Additional selection criteria included: functioning allo-
grafts for at least one year, no past history of diabetes, and
fasting plasma glucose concentration prior to transplan-
tation lower than 126 mg/dL. The characteristics of this
patient population are shown in Table 1. Clinical infor-
mation was retrieved from both paper records and elec-
tronic databases. The extraction and reporting of these
data were approved by the Institutional Review Board.
All patients were asked routinely to provide early morn-
ing blood specimens after an overnight fast. The fasting
status of the patient is indicated in the database. The
pretransplant fasting plasma glucose level closest to the
date of transplant was used for analysis. Post-transplant,
fasting plasma glucose levels were averaged for the fol-
lowing intervals: days 1 to 7 (week one); days 8 to 30
(month one); days 30 to 120 (month four); days 120 to
365 (year one); and last month of follow-up. For the pur-
pose of this analysis, we followed established criteria for
the diagnosis of diabetes mellitus (DM), and for impaired
fasting glycemia (IFG) [10]. Accordingly, patients with
fasting plasma glucose concentrations <100 mg/dL were
considered to have euglycemia; glucose levels between
100 and 125 mg/dL were diagnostic of IFG; and glucose
levels ≥126 mg/dL were diagnostic as PTDM. Further-
more, all patients taking medications to control hyper-
glycemia, either oral agents or insulin, were considered
to have PTDM.
CV events that occurred prior to or after the trans-
plant included the following: (1) ischemic heart disease
was diagnosed when one or more of the following events
were documented: angina pectoris, acute myocardial in-
farction, history of coronary intervention (angioplasty,
stent placement, or coronary bypass surgery), and/or di-
agnosis of ischemic heart disease in the clinic chart; (2)
peripheral vascular disease was diagnosed when one or
more of these events were documented: amputation due
to arterial insufficiency, surgical or radiologic arterial in-
terventions, or chart diagnosis; (3) cerebrovascular acci-
dents (CVA) reported in the chart were also noted. For
statistical analysis, CV events were aggregated into two
total CV scores, one pretransplant and the other post-
transplant. Accordingly, patients were classified as hav-
ing a positive (1) or negative (0) CV score whether or
not they had ischemic heart disease, peripheral vascular
disease, and/or CVA. Patient death was not included in
the total CV score because in many cases we could not
be certain of the cause of the patient’s demise.
Patients received immunosuppression consisting of in-
duction therapy with thymoglobulin (1.5 mg/kg/day for
5–7 days), followed by triple oral immunosuppressive
therapy with corticosteroids, a calcineurin inhibitor (or
sirolimus), and mycophenalate mofetil, generally start-
ing at a dose of 750 mg twice daily. The doses of corti-
costeroids were as follows: solumedrol was administered
intravenously at a dose of 500 mg at the time of trans-
plantation, 250 mg on day one, 125 mg on day two, and
90 mg on day three. On day four, patients were started
on oral prednisone starting at 60 mg daily, and tapered
progressively to achieve a daily dose of 10 mg once daily
at the end of the second month, and 5 mg once daily at
the end of the third month. Tacrolimus or cyclosporine
was initiated when the serum creatinine was <2.5 mg/dL,
generally on day four or five after transplant unless the
patient had delayed graft function. The dose of tacrolimus
was adjusted to achieve trough levels of 10 to 12 ng/mL
(IMX whole blood assay) during the first four months
post-transplant and 6 to 8 ng/mL thereafter. In 66 pa-
tients cyclosporine was used instead of tacrolimus, and in
61 patients sirolimus was used instead of a calcineurin in-
hibitor. Target levels for sirolimus were between 15 and
20 ng/mL for the first four months and 10 to 15 ng/mL
thereafter. These immunosuppressive protocols were not
different in recipients of living donors or deceased donor
grafts.
Data analysis
Data are expressed as mean and standard deviation
of the mean throughout this paper. Chi-square was used
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Fig. 1. Incidence of impaired fasting glucose (IFG, stripped bars) or
PTDM (black bars) at different times post-transplant. The incidence of
these complications at the end of the follow-up (end) was calculated
based on those patients transplanted prior to 2002 (that is, with a mini-
mum follow-up of two years).
to compare proportions. Univariate and multivariate lo-
gistic regression were used to assess the variables that
correlate with hyperglycemia at different times post-
transplant. The relationships among CV events, hyper-
glycemia, and other clinical variables were analyzed in
351 patients transplanted prior to 2002. This subgroup
of patients was selected to allow longer post-transplant
follow-up time. For these analyses, the date of the first
CV event following the transplant was used to calculate
CV event-free survival by both Cox and Kaplan-Meier
survival plots.
RESULTS
Incidence of hyperglycemia at different times after trans-
plantation
Figure 1 displays the percent of allograft recipients with
IFG or DM at different times post-transplant. During the
first week post-transplant, 142 (45%) of recipients had
IFG, and 65 (21%) had PTDM. It should be noted that for
the first four days post-transplant patients were generally
receiving intravenous fluids containing dextrose. Thus,
the definition of “fasting” during this period is question-
able. At the end of the first month, 163 patients (34%) had
persistent IFG, and 68 (14%) remained diabetic. These
latter percentages remained relatively unchanged up to
one year post-transplant, when 155 patients (33%) had
IFG, and 63 (13%) had DM. Among patients with PTDM
at one year, 51% were receiving pharmacologic treatment
for their diabetes, 22% with oral hypoglycemic agents,
and 29% with insulin.
Correlates to the development of hyperglycemia early
post-transplant
Table 2 displays the variables related with the devel-
opment of PTDM at one week and at one year. At both
time points, the risk of PTDM was higher in recipients
of deceased donor kidneys who were older and heavier.
Furthermore, males had a significantly higher risk of
PTDM than females at one year. Regarding biochemical
parameters obtained prior to transplantation, elevated
triglyceride (TG) concentrations were associated with
higher risk of PTDM at one week, and increasing glucose
levels prior to transplantation were related to increasing
risk of PTDM. This latter point is illustrated in Figure 2.
By logistic regression, using patients with pretransplant
glucose levels between 90 and 100 as the reference group
[that is odds ratio (OR) for developing PTDM at one year
= 1], patients with plasma glucose <90 mg/dL have lower
risk of PTDM (OR = .46, P = 0.01). In contrast, the risk
of PTDM increases as the pretransplant fasting glucose
levels increases (glucose 101–110, OR = 1.5; and glucose
110–125, OR = 7.6, P < 0.0001). Among patients with
IFG pretransplant, at one year, 70% had hyperglycemia
(IFG 43% and DM 27%).
Development of hyperglycemia during the first week
post-transplant was statistically the strongest predictor of
PTDM at one year, and this relationship was statistically
independent of all other variables tested (Table 2). For
example, among patients who one week post-transplant
had euglycemia, IFG, or DM, 3%, 14%, and 50% had
PTDM at one year, respectively. Finally, note also that
patients who had PTDM at one year were also more likely
to have a history of CV events pretransplant.
The variables related to the development of IFG at one
year were the same as those shown in Table 2 for PTDM
(not shown). Several additional variables were not signif-
icantly related to the development of post-transplant hy-
perglycemia, including: recipient race (note that 91% of
these patients were Caucasian), total cholesterol, LDL,
or HDL levels prior to transplant, transplant number,
smoking, prior history of dialysis or time on dialysis, fam-
ily history of diabetes, pretransplant use of statins or
angiotensin-converting enzyme inhibitors, year of trans-
plant, hepatitis C (note that only 6 patients had this in-
fection), history of acute rejection episodes, and the use
or type of calcineurin inhibitor. The percent of recipi-
ents who developed PTDM at one year was higher in
patients treated with tacrolimus (28%) or cyclosporine
(29%) than in patients who do not receive calcineurin in-
hibitors (18%). However, these differences did not reach
statistical significance. Similarly, the percent of individ-
uals with IFG at one year or at the end of follow-up
was similar among recipients treated with tacrolimus, cy-
closporine, or a calcineurin inhibitor-free protocol.
Cardiovascular events in patients with post-transplant
hyperglycemia
For these analyses, only those patients transplanted
prior to 2002 were included. The mean follow-up in
these 351 patients was 40 ± 14 months. Table 3 displays
the incidence and type of CV event before and after
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Table 2. Relationship between PTDM, pretransplant, and post-transplant variables
PTDM at one week PTDM at one year
Parameter Univariate Multivariate Univariate Multivariate
Age 1.033 (.003) NS 1.05 (<.0001) 1.05 (<.0001)
BMI pretransplant 1.109 (.001) 1.09 (.008) 1.12 (<.0001) 1.08 (.006)
Pretransplant glucose 1.068 (<.0001) 1.05 (.002) 1.07 (<.0001) 1.05 (.002)
Pretransplant TG 1.002 (.03) NS NS –
Sex (higher risk in males) NS – .49 (.002) 0.4 (.008)
Pretransplant CV events NS – 1.85 (0.01) NS
Donor 3.5 (<.0001) 4.3 (<.0001) 1.5 (.04) NS
























Fig. 2. Percent of patients with IFG (stripped bars) or PTDM (black
bars) one year post-transplant. Patients are divided according to their
fasting blood glucose levels prior to transplant.
Table 3. Incidence of CV events before transplantation and following
transplantation in 351 patients followed for 40 ± 19 months
Pretransplant Post-transplant
CV events (N,%) (N,%)
Cardiac 56 (16%) 33 (9%)
Peripheral vascular disease 7 (2%) 12 (3%)
CVA 0 7 (2%)
Total CV events 62 (18%) 43 (14%)
transplantation in kidney transplant recipients. The in-
cidence of post-transplant CV events is higher in patients
with hyperglycemia. This is shown in Figure 3, which dis-
plays the cumulative incidence of CV events five years
after transplantation in patients classified according to
fasting glucose levels one year post-transplant. As can be
seen, increasing levels of glucose were associated with
increasing cumulative incidence of CV events (hazard
ratio, HR = 1.05, P < 0.0001 by Cox). Considering as
a reference group those patients with a fasting glucose
level between 90 and 100 mg/dL (HR = 1), the HR for
the other groups are: glucose <90: HR = .57, NS; glucose
101–109, HR = 1.69, NS; glucose 110–125, HR = 2.4, P =
0.03; glucose ≥126, HR = 2.9, P = 0.01). Figure 4 displays
the incidence of specific CV events for patients classified
by their glucose levels at one year. To simplify this fig-
ure, patients were classified in three groups: euglycemia,
IFG, and PTDM. The incidence of CVA was not differ-
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Fig. 3. Cumulative incidence of CV events five years post-transplant in
patients classified according to their fasting glycemia at one year. Data



















Fig. 4. Incidence of specific CV events any time post-transplant in pa-
tients who at one year had normal glucose levels (open bars, N = 249),
IFG (stripped bars, N = 48), or DM (black bars, N = 43).
with euglycemia, patients with IFG or PTDM had more
cardiac events (P = 0.001, chi-square), and patients with
PTDM had more peripheral vascular events (P = 0.003,
chi-square). The overall incidence of CV events was sig-
nificantly higher in patients with IFG or PTDM than in
patients with euglycemia (P < 0.001, chi-square).
Table 4 displays the variables significantly related to
post-transplant CV events, including older age, male gen-
der, a history of CV events prior to transplantation, and
more distant transplant year. In addition, CV events were
more common in patients with hyperglycemia at one
Cosio et al: New onset hyperglycemia, diabetes, and cardiovascular risk after transplantation 2419
Table 4. Variables associated with the occurrence of any CV events
following transplantation (N = 351, Cox regression)
Univariable Multivariable
Parameter (OD, P value) (OD, P value)
Age 1.05 (<.0001) 1.03 (.05)
Sex (higher risk in males) .27 (.002) .44 (.05)
Pretransplant CV eventsa 2.1 (.01) NS
Transplant year 2.3 (<.0001) 2.7 (<.0001)
Glycemiab at 1 month 1.04 (.001) 1.02 (.03)c
Glycemiab at 4 months 1.06 (<.0001) 1.03 (.002)c
Glycemiab 1 year 1.06 (<.0001) 1.04 (.006)c
HDLc at 1 year .97 (.03) NS
aIncludes patients with history of heart disease, CVA, and/or peripheral
vascular disease.
bGlycemia was analyzed in groups as described in Figure 3.
cEach level of glycemia was entered separately into the multivariable model.
The statistics for age, sex, pretransplant CV, and transplant year correspond to
the multivariable model, including the one-year glycemia.
month, four months, and/or one year post-transplant.
Finally, it should be noted that low HDLc was also as-
sociated with increased CV risk. Related to this latter
observation, compared to euglycemia, IFG and PTDM
are associated with lower HDLc at one year (euglycemia,
55 ± 16; IFG, 49 ± 13; PTDM, 48 ± 15 mg/dL, P < 0.0001,
ANOVA) and higher TG levels (euglycemia, 196 ± 119;
IFG, 224 ± 122; PTDM, 241 ± 165 mg/dL, P = 0.007,
Kruskall-Wallis). In contrast, total cholesterol and LDLc
did not differ among groups.
By multivariable analysis (Table 4), post-transplant
CV events relate to older age, male gender, more dis-
tant transplant year, and fasting hyperglycemia at either
one, four, and/or 12 months post-transplant. It should be
noted that recipient age and pretransplant history of CV
events were closely inter-related. Thus, in some multivari-
able models, for example, that including glycemia at four
months, the history of CV events, and not age was related
to post-transplant CV events. Figure 5 displays the rela-
tionships between glycemia at one year and CV events.
As can be seen, patients with IFG and PTDM were at
higher risk of CV events than patients with euglycemia
(P = 0.001 by log rank). Additional variables did not re-
late with post-transplant CV events, including: pretrans-
plant levels of glucose, lipids, uric acid, or BMI, donor
type, length of dialysis prior to the transplant, type of
post-transplant immunosuppression one year after trans-
plantation, history of previous transplants, total choles-
terol, TG, or LDLc levels at one year, and the use of
statins or angiotensin-converting enzyme inhibitors at
one year post-transplant.
Some patients with hyperglycemia at one month were
no longer hyperglycemic on follow-up. To determine the
CV risk of those patients we divided patients one month
post-transplant into three groups: euglycemia (N = 255),
PTDM (N = 44), and PTDM that resolved during follow-
up (N = 31). Compared to patients with euglycemia, the
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Fig. 5. Incidence of CV events in patients with normal glycemia
(N = 356, —), patients with IFG (N = 58,—), and patients with PTDM
(N = 63, —) at one year (P = 0.0005, log rank).
with persistent PTDM (HR = 1.7, P = 0.005 by Cox), but
not in those in whom the PTDM resolved. The incidence
of CV events in these three groups of individuals was
euglycemia: 11%, PTDM: 23%, and PTDM that resolves:
10%.
At the end of follow-up 16 patients died (4.6%), and 27
lost their graft for causes other than patient death (7.8%).
Glycemia at one year post-transplant did not relate signif-
icantly with patient survival or with death-censored graft
survival. However, hyperglycemia was related to higher
uncensored graft survival (HR = 1.6, P = 0.01).
DISCUSSION
With some exceptions [13], previous studies on PTDM
have not used ADA criteria for the diagnosis of diabetes
in kidney transplant patients. The results of this study
strongly support previous suggestions [1, 14] that these
ADA criteria [9, 10] should be applied to these patients.
For example, the use of hypoglycemic agents as diagnos-
tic criteria for PTDM is inaccurate and, in fact, we showed
here that more than half of the patients with PTDM were
not receiving hypoglycemic agents. In addition, it is likely
that patients with lesser levels of hyperglycemia are not
diagnosed of DM and, thus, are not included in those stud-
ies that use chart diagnoses as criteria to identify patients
with PTDM. Finally, the strongest argument in favor of
using standard ADA criteria to classify hyperglycemia is
the observation made here that levels of fasting glucose
generally classified as “mildly elevated” were associated
with increased CV risk.
One of the hypotheses that we sought to test in this
study is that patients who develop PTDM after the first
year have hyperglycemia earlier post-transplant. These
results confirm this hypothesis. Thus, 89% of patients with
PTDM at one year had hyperglycemia at one week, and
91% of patients with PTDM at the end of follow-up had
hyperglycemia at one year. Furthermore, 100% of pa-
tients with PTDM at four and/or 12 months had PTDM
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at the end of the follow-up period. Although glucose lev-
els one week post-transplant were the strongest predictor
of future PTDM, clearly not all patients with early hyper-
glycemia remained hyperglycemic. Still, the presence of
hyperglycemia at one week is notable and should alert the
physician that the patient is at high risk of DM, CV com-
plications, and reduced graft survival. Additional vari-
ables are associated with an increased risk of PTDM. For
example, these results confirm the higher risk of PTDM in
older, heavier recipients, and in males (reviewed in [1]).
Furthermore, those associations are also valid for IFG. In
apparent contrast to previous studies, this study did not
find associations between PTDM and African American
race, hepatitis C, family history of diabetes, and the use of
calcineurin inhibitors. However, this is most likely due to
the characteristics of our study population (very few non-
Caucasian recipients and a very low incidence of hepatitis
C), and also perhaps due to the fact that we focused on
the hyperglycemia that occurs early post-transplant.
In this study we also assessed whether pretransplant
biochemical markers of insulin resistance could help
better define the risk of post-transplant hyperglycemia.
Among those, the level of fasting glycemia pretrans-
plant is the strongest risk factor for post-transplant hy-
perglycemia (see Fig. 2). One of the original intents of
the ADA expert panel in defining IFG was to identify
patients at future risk of DM [10]. In our population of
kidney transplant recipients this association was strong
and similar to that shown in Pima Indians [15]. Still, it
should be noted that most patients who later developed
hyperglycemia had normal fasting glucose levels prior to
the transplant (see Fig. 2). Furthermore, other biochem-
ical markers that may identify patients with insulin resis-
tance pretransplant were either weakly associated (such
as the elevated TG), or not associated with risk of PTDM
(such as uric acid and HDLc). This lack of association is
reminiscent of the unusual associations between lipid lev-
els and CV risk in patients with chronic kidney disease
[16], perhaps reflecting the fact that, in these patients,
nutritional status is an important confounder in the inter-
pretation of lipid levels.
The results of this study show a strong association be-
tween fasting hyperglycemia and CV risk post-transplant.
In the general population, there is an association between
fasting hyperglycemia and CV risk [12, 17], although that
association appears to be stronger in some groups than
in others [9]. These results suggest that in transplant re-
cipients, as in other populations [18], there may be a
continuous relationship between increasing levels of fast-
ing plasma glucose and CV risk (see Fig. 3). As shown
here and elsewhere [5–7], transplant recipients experi-
ence an unusually short interval between the onset of
hyperglycemia, increased CV risk, and mortality. We and
others suggested that this short interval may be due to the
fact that PTDM occurs in patients who already have CV
disease pretransplant, at least in part due to unrecognized
abnormalities in glucose metabolism. These results lend
support to this hypothesis by showing that patients who
develop PTDM at one year have a high incidence of pre-
transplant CV events. However, against this hypothesis is
the observation that 75% of patients who develop PTDM
have normal fasting glucose levels pretransplant. It is pos-
sible that patients with chronic kidney disease have a high
incidence of postprandial hyperglycemia and/or insulin
resistance that were not detected in this study. Both of
these abnormalities are associated with increased CV risk
[11, 19]. It is also possible that, compared to the general
population, hyperglycemia may have an enhanced dele-
terious effect on the CV system of patients with chronic
kidney disease and/or post-transplant. In this context,
it is interesting to note that previous studies showed a
stronger association between DM and mortality in trans-
plant recipients than in the general population [20].
The association between post-transplant hyper-
glycemia and CV disease was statistically independent
of other risk factors tested here, including: older age,
male gender, history of CV disease, and dyslipidemia.
However, physiologically and clinically, all of these vari-
ables are closely related. Consequently, attempts to
reduce the CV risk of transplant recipients need to ad-
dress all CV risk factors. These results suggest that this
approach should include careful assessment of glycemia
and its treatment. As shown here, approximately half
of the patients with glucose levels diagnostic of dia-
betes received pharmacologic treatment. We cannot de-
termine how many of patients with hyperglycemia were
given advice regarding lifestyle modifications. This non-
pharmacologic approach is effective and highly justifi-
able [21, 22]. However, we should also recognize that in
this patient population, these measures are rarely effec-
tive. In addition, the high CV risk of kidney transplant
recipients justifies a more aggressive treatment of risk
factors, such as dyslipidemia [23] and perhaps also hy-
perglycemia. Modifications in immunosuppressive ther-
apy likely would improve glucose metabolism [24–26].
However, those changes should be considered only when
they are safe for the allograft [27]. Certain hypoglycemic
agents reduce the risk of DM in high-risk populations
[21, 28, 29], but we have no data in transplant patients.
Furthermore, there is no evidence that treatment of IFG
reduces CV risk in the general population (reviewed in
[9]). We suggest that these studies are urgently needed in
transplant recipients.
These analyses are limited by both the characteristics
of the population and the lack of data on other mea-
surements of glycemia. Considering these limitations, it
is likely that this study underestimates the true incidence
of post-transplant hyperglycemia and its associated CV
risk. Thus, African Americans and Hispanics, two pop-
ulations with high risk of DM, are under-represented in
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our population. These analyses do not include measure-
ments of postprandial glycemia, a parameter that corre-
lates with CV risk better than fasting glycemia [11, 12].
Glycosylated hemoglobin (HbA1c) is not reported in this
study. However, this parameter is most often in the nor-
mal range in patients with IFG and, thus, is likely not
helpful in the diagnosis of hyperglycemia and assessment
of risk [9].
The success of kidney transplantation is limited by high
CV risk and premature death of the recipient. Several
previous studies identified a high incidence of traditional
CV risk factors in this population. However, the excess
mortality of transplant patients compared to the general
population remains unexplained. The results of this study
suggest that hyperglycemia may be a significant contribu-
tor to the CV risk of transplant recipients. Whether treat-
ment of post-transplant hyperglycemia reduces CV risk
needs to be tested prospectively.
Reprint requests to Fernando G. Cosio, M.D., Mayo Clinic, 200 1st St.
SW, Rochester, MN 55905.
E-mail: Cosio.Fernando@mayo.edu
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